Browse > Article
http://dx.doi.org/10.22742/JIG.2021.3.2.41

Review of Genetic Diagnostic Approaches for Glanzmann Thrombasthenia in Korea  

Shim, Ye Jee (Department of Pediatrics, Keimyung University School of Medicine, Keimyung University Dongsan Hospital)
Publication Information
Journal of Interdisciplinary Genomics / v.3, no.2, 2021 , pp. 41-46 More about this Journal
Abstract
Inherited platelet function disorders (IPFDs) are a disease group of heterogeneous bleeding disorders associated with congenital defects of platelet functions. Normal platelets essential role for primary hemostasis by adhesion, activation, secretion of granules, aggregation, and procoagulant activity of platelets. The accurate diagnosis of IPFDs is challenging due to unavailability of important testing methods, including light transmission aggregometry and flow cytometry, in several medical centers in Korea. Among several IPFDs, Glanzmann thrombasthenia (GT) is a most representative IPFD and is relatively frequently found compare to the other types of rarer IPFDs. GT is an autosomal recessive disorder caused by mutations of ITGA2B or ITGB3. There are quantitative or qualitative defects of the GPIIb/IIIa complex in platelet, which is the binding receptor for fibrinogen, von Willbrand factor, and fibronectin in GT patients. Therefore, patients with GT have normal platelet count and normal platelet morphology, but they have severely decreased platelet aggregation. Thus, GT patients have a very severe hemorrhagic phenotypes that begins at a very early age and persists throughout life. In this article, the general contents about platelet functions and respective IPFDs, the overall contents of GT, and the current status of genetic diagnosis of GT in Korea will be reviewed.
Keywords
Blood platelet disorders; Thrombasthenia; Platelet function tests; High-throughput nucleotide sequencing; Whole exome sequencing; Whole genome sequencing;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Alamelu J, Liesner R. Modern management of severe platelet function disorders. British journal of haematology 2010;149:813-23.   DOI
2 Ambo H, Kamata T, Handa M, Kawai Y, Oda A, Murata M, et al. Novel point mutations in the alphaIIb subunit (Phe289-->Ser, Glu324-->Lys and Gln747-->Pro) causing thrombasthenic phenotypes in four Japanese patients. Br J Haematol 1998;102:829-40.   DOI
3 Tanaka S, Hayashi T, Hori Y, Terada C, Han KS, Ahn HS, et al. A Leu55 to Pro substitution in the integrin alphaIIb is responsible for a case of Glanzmann's thrombasthenia. Br J Haematol 2002; 118:833-5.   DOI
4 Lentaigne C, Freson K, Laffan MA, Turro E, Ouwehand WH; BRIDGE-BPD Consortium and the ThromboGenomics Consortium. Inherited platelet disorders: toward DNA-based diagnosis. Blood 2016;127:2814-23.   DOI
5 Broos K, Feys HB, De Meyer SF, Vanhoorelbeke K, Deckmyn H. Platelets at work in primary hemostasis. Blood Reviews 2011;25: 155-67.   DOI
6 Jung N, Shim YJ. Current knowledge on inherited platelet function disorders. Clin Pediatr Hematol Oncol 2020;27:1-13.   DOI
7 Nurden AT, Fiore M, Nurden P, Pillois X. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood 2011; 118:5996-6005.   DOI
8 Fang J, Nurden P, North P, Nurden AT, Du LM, Valentin N, et al. C560Rbeta3 caused platelet integrin alphaII b beta3 to bind fibrinogen continuously, but resulted in a severe bleeding syndrome and increased murine mortality. J Thromb Haemost 2013;11:1163-71.   DOI
9 Kato A, Yamamoto K, Miyazaki S, Jung SM, Moroi M, Aoki N. Molecular basis for Glanzmann's thrombasthenia (GT) in a compound heterozygote with glycoprotein IIb gene: a proposal for the classification of GT based on the biosynthetic pathway of glycoprotein IIb-IIIa complex. Blood 1992;79:3212-8.   DOI
10 George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 1990;75:1383-95.   DOI
11 Yang EJ, Shim YJ, Kim HS, Lim YT, Im HJ, Koh KN, et al. Genetic Confirmation and Identification of Novel Variants for Glanzmann Thrombasthenia and Other Inherited Platelet Function Disorders: A Study by the Korean Pediatric Hematology Oncology Group (KPHOG). Genes (Basel) 2021;12.
12 Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996;88:907-14.   DOI
13 Tanaka S, Hayashi T, Terada C, Hori Y, Han KS, Ahn HS, et al. Glanzmann's thrombasthenia due to a point mutation within intron 10 results in aberrant splicing of the beta3 gene. J Thromb Haemost 2003;1:2427-33.   DOI
14 Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Seminars in thrombosis and hemostasis 2005;31:381-92.   DOI
15 Shim YJ. Genetic classification and confirmation of inherited platelet disorders and current status in Korea. Korean J Pediatr 2019.
16 Grainger JD, Thachil J, Will AM. How we treat the platelet glycoprotein defects; Glanzmann thrombasthenia and Bernard Soulier syndrome in children and adults. Br J Haematol 2018;182:621-32.   DOI
17 Leebeek FW, Eikenboom JC. Von Willebrand's Disease. N Engl J Med 2016;375:2067-80.   DOI
18 Smyth SS, McEver RP, Weyrich AS, Morrell CN, Hoffman MR, Arepally GM, et al. Platelet functions beyond hemostasis. Journal of thrombosis and haemostasis : JTH 2009;7:1759-66.   DOI
19 Holinstat M. Normal platelet function. Cancer metastasis reviews 2017;36:195-8.   DOI
20 Afrasiabi A, Artoni A, Karimi M, Peyvandi F, Ashouri E, Mannucci PM. Glanzmann thrombasthenia and Bernard-Soulier syndrome in south Iran. Clin Lab Haematol 2005;27:324-7.   DOI
21 Bastida Bermejo JM, Hernandez-Rivas JM, Gonzalez-Porras JR. Novel approaches for diagnosing inherited platelet disorders. Med Clin (Barc) 2017;148:71-7.   DOI
22 Iqbal I, Farhan S, Ahmed N. Glanzmann Thrombasthenia: A Clinicopathological Profile. J Coll Physicians Surg Pak 2016;26:647-50.
23 Bolton-Maggs PH, Chalmers EA, Collins PW, Harrison P, Kitchen S, Liesner RJ, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006;135:603-33.   DOI
24 Lee A, Poon M-C. Inherited platelet functional disorders: General principles and practical aspects of management. Transfusion and apheresis science: official journal of the World Apheresis Association: official journal of the European Society for Haemapheresis 2018;57:494-501.   DOI
25 Zotz RB, Poon M-C, Di Minno G, D'Oiron R, Glanzmann Thrombasthenia Registry I. The International Prospective Glanzmann Thrombasthenia Registry: Pediatric Treatment and Outcomes. TH open: companion journal to thrombosis and haemostasis 2019;3:e286-94.
26 Botero JP, Lee K, Branchford BR, Bray PF, Freson K, Lambert MP, et al. Glanzmann thrombasthenia: genetic basis and clinical correlates. Haematologica 2020;105:888-94.   DOI
27 Park KJ, Chung HS, Lee KO, Park IA, Kim SH, Kim HJ. Novel and recurrent mutations of ITGA2B and ITGB3 genes in Korean patients with Glanzmann thrombasthenia. Pediatr Blood Cancer 2012;59:335-8.   DOI
28 Ambo H, Kamata T, Handa M, Taki M, Kuwajima M, Kawai Y, et al. Three novel integrin beta3 subunit missense mutations (H280P, C560F, and G579S) in thrombasthenia, including one (H280P) prevalent in Japanese patients. Biochem Biophys Res Commun 1998;251:763-8.   DOI
29 Simeoni I, Stephens JC, Hu F, Deevi SV, Megy K, Bariana TK, et al. A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. Blood 2016;127: 2791-803.   DOI
30 Tanaka S, Hayashi T, Yoshimura K, Nakayama M, Fujita T, Amano T, et al. Double heterozygosity for a novel missense mutation of Ile304 to Asn in addition to the missense mutation His280 to Pro in the integrin beta3 gene as a cause of the absence of platelet alphaIIbbeta3 in Glanzmann's thrombasthenia. J Thromb Haemost 2005;3:68-73.   DOI